Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis & Investment Frameworks
Xeris Biopharma Holdings, Inc. (XERS) stock analysis on Invetso. Review Xeris Biopharma Holdings, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Xeris Biopharma Holdings, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Xeris Biopharma Holdings, Inc. Key Financial Metrics
- Market Cap: $1.97B
- Revenue: $291.85M
- ROE: -426.33%
- ROIC: 12.51%
- Dividend Yield: N/A
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Xeris Biopharma Holdings, Inc. Investment Frameworks
Invetso analyzes Xeris Biopharma Holdings, Inc. (XERS) across the following frameworks:
- Xeris Biopharma Holdings, Inc. 10Y Growth Potential
- Xeris Biopharma Holdings, Inc. Scenario Analysis
- Xeris Biopharma Holdings, Inc. Risks & Opportunities
- Xeris Biopharma Holdings, Inc. Economic Moat
- Xeris Biopharma Holdings, Inc. Business Model
- Xeris Biopharma Holdings, Inc. Management
- Xeris Biopharma Holdings, Inc. SWOT Analysis
- Xeris Biopharma Holdings, Inc. Porter's 5 Forces
- Xeris Biopharma Holdings, Inc. PESTLE Analysis
- Xeris Biopharma Holdings, Inc. ESG Analysis